Durham-based Precision BioSciences Inc. has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for PBGENE-HBV, an in vivo gene editing program designed ...

Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class ...

While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the body's defences are unable to ...

Precision aims to define the optimal dose and number of administrations for the elimination of covalently closed circular DNA (cccDNA), in addition to the inactivation of integrated HBV DNA.

Chronic hepatitis B infection is primarily driven by persistence of HBV cccDNA and integration of HBV DNA into the human genome in liver cells, the primary source of hepatitis B surface antigen ...

Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...

The genetic and epigenetic alterations in cell-free DNA (cfDNA ... Mutation Capsule can read out the integration of the hepatitis B virus (HBV) gene in a fraction of human gene sequences, as ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need ...